Getting Phase I trials right first time
How to ensure your Phase I trials comply with quality and regulatory expectations, long-term.
Quality of clinical data, competitive timelines, and cost-effectiveness: these are just some of the numerous considerations that Biopharma and MedTech companies need to think about when conducting clinical studies.
Creating high-quality clinical data facilitates good clinical development decision-making, enhances the quality of a drug Marketing Authorisation Application (MAA) dossier, and mitigates long-term regulatory vulnerabilities. Shortcomings in the clinical data that support MAA dossiers can potentially result in unreliable outcomes, sometimes leading to entire clinical studies needing to be redone.
Mitigating risk in Phase I trials
Phase I clinical trials are especially susceptible to these outcomes due to their short-term duration. Deficiencies in the clinical trial that result in poor-quality clinical data can jeopardise the integrity of the entire MAA dossier. Choosing a clinical site and a CRO with an excellent track record of audits and a commitment to maintaining the highest standards to achieve data quality is not just a strategic decision, but a safeguard against setbacks in clinical development.
Getting Phase I trials right the first time is crucial for lean and effective drug development. This approach prevents the doubling of costs, both opportunity and financial, and, equally importantly, avoids the duplication of drug exposure for study participants.
Staying up to date with the latest clinical standards
Being informed of the latest standards is paramount for all stakeholders in clinical research, including Sponsors and CROs. It requires a continuous commitment while always monitoring the most advanced scientific developments.
Keeping pace with these can be resource-intensive, and this is exemplified by the US FDA Study Data Technical Conformance Guide. This document provides specifications and recommendations on how to submit standardised study data according to the agency’s requirements. It was updated on six different occasions in 2023 and impacted operations across various organisations.
Understanding these changes ensures compliance with regulatory expectations and better positions organisations to generate high-quality clinical data. This creates the best possible foundation for successful research outcomes.
Prioritising excellence in Phase I trials and staying current with evolving standards is integral to efficient drug development. By embracing these practices, stakeholders can mitigate costs, enhance data quality, and position themselves for success across the clinical research landscape.
Getting Phase I trials right the first time is crucial for lean and effective drug development. This approach prevents the doubling of costs, both opportunity and financial, and, equally importantly, avoids the duplication of drug exposure for study participants.
Astrum has the understanding for conducting successful Phase I trials.
Would you like to know more?